• Celgene’s Pomalyst secures breakthrough designation pharmaceutical-technology
    May 16, 2019
    The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to Celgene’s Pomalyst (pomalidomide) in HIV-positive and HIV-negative Kaposi sarcoma.
PharmaSources Customer Service